Therapeutic targeting of prostate-specific membrane antigen could limit its potential as benchmark imaging

Affiliations

¹ Genitourinary Malignancies Branch, National Cancer Institute, Bethesda, MD, USA.
² Institute of Cancer Research, Royal Marsden NHS Foundation Trust, London, UK.
³ Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
⁴ Molecular Imaging Branch, National Cancer Institute, Bethesda, MD, USA.
⁵ Genitourinary Malignancies Branch, National Cancer Institute, Bethesda, MD, USA. madanr@mail.nih.gov.

Melissa L Abel et al. Nat Rev Urol. 2025.

. 2025 Oct 13.

doi: 10.1038/s41585-025-01100-z. Online ahead of print.

¹ Genitourinary Malignancies Branch, National Cancer Institute, Bethesda, MD, USA.
² Institute of Cancer Research, Royal Marsden NHS Foundation Trust, London, UK.
³ Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
⁴ Molecular Imaging Branch, National Cancer Institute, Bethesda, MD, USA.
⁵ Genitourinary Malignancies Branch, National Cancer Institute, Bethesda, MD, USA. madanr@mail.nih.gov.

No abstract available

Conflict of interest statement

Competing interests: The authors declare no competing interests.

1. Sartor, O. et al. Lutetium-177-PSMA-617 for metastatic castration-resistant prostate cancer. N. Engl. J. Med. 385, 1091–1103 (2021). - DOI - PubMed - PMC
1. Pienta, K. J. et al. A phase 2/3 prospective multicenter study of the diagnostic accuracy of prostate specific membrane antigen PET/CT with ¹⁸F-DCFPyL in prostate cancer patients (OSPREY). J. Urol. 206, 52–61 (2021). - DOI - PubMed - PMC
1. Morris, M. J. et al. ¹⁷⁷Lu-PSMA-617 versus a change of androgen receptor pathway inhibitor therapy for taxane-naive patients with progressive metastatic castration-resistant prostate cancer (PSMAfore): a phase 3, randomised, controlled trial. Lancet 404, 1227–1239 (2024). - DOI - PubMed - PMC
1. Sartor, A. O. et al. PSMA-delay castration (DC): an open-label, multicenter, randomized phase 3 study of [177Lu]Lu-PSMA-617 versus observation in patients with metachronous PSMA-positive oligometastatic prostate cancer (OMPC). J. Clin. Oncol. 43 (Suppl. 16), TPS5127 (2025).
1. Mulati, Y. et al. Characterizing PSMA heterogeneity in prostate cancer and identifying clinically actionable tumor associated antigens in PSMA negative cases. Sci. Rep. 15, 23902 (2025). - DOI - PubMed - PMC